There is also an ongoing cardiovascular outcomes trial of tirzepatide (SURPASS-CVOT) in individuals with type 2 diabetes and cardiovascular disease [91], which, if successful, will broaden the use of tirzepatide to those with manifest or increased risk for CVD, as is the case for GLP-1 receptor agonists [22]
A broader expression of the obesity-drug theme sits in the Health Care Select Sector SPDR (XLV.P), available as a CFD on EBC Financial Groups ETF platform, which holds Eli Lilly inside a diversified large-cap healthcare basket
Dinic, J., Podolski-Renic, A., Jeremic, M
Read the full article.
Mt s cu hi thng gp
Sedentary behavior is associated with insulin resistance and reduced energy expenditure, potentially blunting tirzepatide's metabolic benefits